Companies and Markets
Market Research A to Z | Company Profiles A to Z | Register | Contact Us
+44 (0) 203 086 8600 Call us on

Hyperparathyroidism market growth to be driven by the launch of two novel drugs

Industry Sector

Healthcare and Medical

Published

12 November 2012

Author

Mike King

Type of News

Market

The hyperparathyroidism market has been forecast to increase at a compound annual growth rate (CAGR) of 3.3% over the next seven years, increasing from a valuation of $2.01 billion in 2011 to reach a market value of $2.62 billion by 2019.

Hyperparathyroidism is over activity of the parathyroid glands resulting in excess production of parathyroid hormone (PTH). The parathyroid hormone regulates calcium and phosphate levels and helps to maintain these levels. Excessive PTH secretion may be due to problems in the glands themselves, in which case it is referred to as primary hyperparathyroidism and which leads to hypercalcaemia (raised calcium levels).

This moderate growth within the hyperparathyroidism market can be primarily attributed to the increase in the hyperparathyroidism patient population and the expected launches of two novel drugs: CTAP101 and KAI-4169 IV.

Hyperparathyroidism patients can expect a slow but steady change in treatment options, as pharmaceutical companies work through stringent clinical trials.

Significant opportunities still exist for novel molecules and novel formulations, and several new treatments are anticipated - including CTAP101 capsules, expected to be launched in the US in 2015, KAI-4169 IV in the US in 2016, and KAI-4169 IV in the EU5 (France, Germany, Italy, Spain, and the UK) in 2017.

Cytochroma's CTAP101 is a First-in-Class (FIC), vitamin D pro-hormone, which is hoped will enable the effective control of elevated PTH levels and correction of underlying vitamin D insufficiency in CKD stage 3 and 4 patients. Currently, CTAP101 is the only molecule in Phase III clinical trials.

KAI Pharmaceuticals (an Amgen company) is developing KAI-4169 IV,an FIC, second-generation, optimized Calcium-Sensing Receptor (CaSR) agonist, which has shown improved efficacy, tolerability and patient compliance with low adverse effects in CKD stage 5 patients, in Phase II trial results.

For more information on the hyperparathyroidism market, see the latest research: Hyperparathyroidism Market

Follow us on Twitter @CandMResearch

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings